SEC Form 4 · accession 0001144204-16-079047
CorMedix Inc. · CRMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Steven W Lefkowitz
Director
Period of report
Feb 4, 2016
Accepted (ET)
Feb 4, 2016 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001410098
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value per share | Feb 4, 2016 | M | 30,000 | $0.29 | A | 147,399 | D | |
| Common Stock, $0.001 par value per shareF1 | holding | — | — | — | 174,741 | I | Wade Capital Corporation Money Purchase Plan | |
| Common Stock, $0.001 par value per shareF1 | holding | — | — | — | 10,000 | I | Reporting Person's Wife |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F7 | $0.29 | Feb 4, 2016 | M | 30,000 | D | — | Jan 6, 2022 | Common Stock, $0.001 par value per share | 30,000 | 0 | D |
| Stock Option (right to buy)F2 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 200,000 | 200,000 | D |
| Stock Option (right to buy)F7 | $2.02 | holding | — | — | — | — | Jan 9, 2024 | Common Stock, $0.001 par value per share | 30,000 | 30,000 | D |
| Swries C-3 Non-Voting Convertible Preferred StockF3 | $1.00 | holding | — | — | — | — | — | Common Stock, $0.001 par value per share | 45,000 | 4,500 | D |
| Warrant (right to purchase Common Stock)F4 | $0.90 | holding | — | — | — | Jan 8, 2015 | Jan 8, 2020 | Common Stock, $0.001 par value per share | 22,500 | 22,500 | D |
| Series C-3 Non-Voting Convertible Preferred StockF1,F4 | $1.00 | holding | — | — | — | — | — | Common Stock, $0.001 par value per share | 30,000 | 3,000 | I |
| Warrant (right to purchase Common Stock)F1,F4 | $0.90 | holding | — | — | — | Jan 8, 2015 | Jan 8, 2020 | Common Stock, $0.001 par value per share | 15,000 | 15,000 | I |
| Stock Option (right to buy)F5 | $0.90 | holding | — | — | — | — | Mar 20, 2023 | Common Stock, $0.001 par value per share | 120,000 | 120,000 | D |
| Stock Option (right to buy)F6 | $0.68 | holding | — | — | — | — | Dec 5, 2022 | Common Stock, $0.001 par value per share | 150,000 | 150,000 | D |
| Stock Option (right to buy)F8 | $1.10 | holding | — | — | — | — | Aug 11, 2021 | Common Stock, $0.001 par value per share | 30,000 | 30,000 | D |
| Stock Option (right to buy)F7 | $5.62 | holding | — | — | — | — | Mar 1, 2025 | Common Stock, $0.001 par value per share | 50,000 | 50,000 | D |
Explanation of responses
- F1The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
- F2The options vested 100% on January 10, 2014.
- F3On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
- F4On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The warrant exercise price was decreased from $1.25 per share to $0.90 per share effective September 15, 2014. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
- F5These options vest quarterly over two years beginning June 13, 2013.
- F6These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
- F7The options vest in full on the first anniversary of the date of grant.
- F8The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.